Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01163526 · ClinicalTrials.gov registry record
Perfusion CT as a Predictor of Treatment Response in Patients With Hepatic Malignancies
A clinical trial, sponsored by Stanford University.
- Terminated
- Registry status
- 13
- Enrollment target
NCT01163526: Clinical Trial study, sponsored by Stanford University.
NCT01163526 is a clinical trial that was terminated before completion, run by Stanford University. The registered enrollment target is 13 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01163526 was terminated before completion, sponsored by Stanford University.
- TERMINATED
- Registry status
- 13 participants
- Enrollment target
Study Summary
A research study of liver perfusion (how blood flows to the liver over time). We hope to learn whether perfusion characteristics of liver masses may be predictive of response to treatment and whether liver perfusion characteristics can be used to follow response to treatment.
Interventions
- PROCEDURE CT perfusion
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 13 participants |
| Start Date | 2010-09 |
| Est. Completion | 2016-07 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01163526
The ClinicalTrials.gov registry entry for NCT01163526 describes a study currently listed as terminated, categorized as an unspecified phase. The registered enrollment target is 13 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Stanford University, which has 1,744 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which CT perfusion is the first listed.
NCT01163526 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01163526 about?
NCT01163526 is a clinical study titled "Perfusion CT as a Predictor of Treatment Response in Patients With Hepatic Malignancies". A research study of liver perfusion (how blood flows to the liver over time). We hope to learn whether perfusion characteristics of liver masses may be predictive of response to treatment and whether liver perfusion characteristics can be used to follow response to treatment.
What is the current status of trial NCT01163526?
This trial is currently terminated. The enrollment target is 13 participants. The study started on 2010-09. Estimated completion is 2016-07.
What interventions are being tested in trial NCT01163526?
The interventions under investigation include: CT perfusion (PROCEDURE).
Who is sponsoring clinical trial NCT01163526?
This trial is sponsored by Stanford University, which has 1,744 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.